Methods for analysis of multiple cystic fibrosis mutations
β Scribed by Ivy S. L. Ng; Robert Pace; Michael V. Richard; Keiko Kobayashi; Bat-sheva Kerem; Lap-Chee Tsui; Arthur L. Beaudet
- Publisher
- Springer
- Year
- 1991
- Tongue
- English
- Weight
- 583 KB
- Volume
- 87
- Category
- Article
- ISSN
- 0340-6717
No coin nor oath required. For personal study only.
β¦ Synopsis
A large number of mutations causing cystic fibrosis (CF) have been reported. In an attempt to improve methods for genetic diagnosis and for heterozygote screening, we evaluated methods for efficient analysis of the delta F508, G542X, G551D, R553X, and N1303K mutations. We found that multiple mutations can be analyzed simultaneously using hybridization with allele-specific oligonucleotides. Alternatively all of these mutations can be detected by amplification of DNA followed by restriction enzyme digestion and analysis on polyacrylamide gels. A previously reported method for use of modified primers for DNA amplification to allow detection of virtually any single-base change by restriction enzyme analysis proved particularly useful. The common delta F508 mutation and three mutations in exon 11 were analyzed using a multiplex amplification reaction followed by double digestion with restriction enzymes and electrophoresis in a single lane on a polyacrylamide gel. In a sample of 439 CF chromosomes from North American Caucasians, the frequencies of various mutations were as follows: delta F508 = 75.8%, G542X = 2.7%, G551D = 3.2%, R553X = 1.4%, and N1303K = 1.4% for a total of 84.5% detection of CF chromosomes by analysis for these five mutations.
π SIMILAR VOLUMES
We carried out molecular analysis of 80 chromosomes from 40 unrelated Mexican patients with a diagnosis of cystic fibrosis. The study was performed in two PCR steps: a preliminary one to identify mutation β¬F508, the most frequent cause of cystic fibrosis worldwide, and the second a reverse dot-blot
regarding the manuscript are gratefully acknowledged. The operating cost of the Consortium is supported by a grant from the Cystic Fibrosis Foundation of the USA.
Communicated by Gamy R